Most Read Life Sciences Brexit News Stories on AcornRegulatory.com in 2016
We appear to have become accustomed to the phrase ‘no one foresaw this happening’. The term certainly applies to those of us taken by surprise in the early hours of June 24th 2016 when the announcement was made that the...
Acorn Regulatory News Roundup December 2016
In Acorn Regulatory News for December 2016 we are looking back at five of the stories over the past month that have caught your attention on our website and through our social media channels.
EMA Guidelines on First in Human Trials Revised
The EMA guidelines on first in human clinical trials have been revised. The European Medicines Agency issued its proposed revisions to the 2007 guideline earlier this week (November 15th).
Brexit & Regulatory Affairs – The UK Is Heading for the Exit
In an extract from our second Brexit whitepaper, we look at the impact of Brexit on regulatory affairs and issues such as the future of the European Medicines Agency, Pharmacovigilance and Brexit and much more.
Download Our Latest Brexit Whitepaper – Heading for the Exit
Where Next for the European Medicines Agency? In our second Brexit whitepaper, we are looking at the implications of the decision to leave on one of the most ‘mission-critical’ agencies of the EU – the European Medicines Agency. The future...
Industry Bodies Come Together To Host BioPharma Ambition.
Minister Simon Harris’ confirmation that the Irish government will soon be making a bid to be the new home of the EMA was one of the main talking points at the first BioPharma Ambition conference in Dublin.
Acorn Regulatory Monthly Newsletter: September 2016
We have just launched our new Acorn Regulatory monthly newsletter. You can read all of the stories from the newsletter here. If you are not already subscribing then sign up to receive the next edition.
The Implications of Brexit for the Life Sciences Sector
The implications of Brexit are still being felt. Politically, the decision has triggered a chain of events that none of us could have ever foreseen. Now, with a new Prime Minister in Downing Street and three leading ‘Brexiteers’ appointed to offices...
EMA Introduces New Chapter on Good Pharmacovigilance Practices (EU-GVP)
The European Medicines Agency has added a new chapter (Product- or population-specific considerations II: Biological medicinal products) to its guidelines on good pharmacovigilance practices – EU GVP. The new GVP guidance comes into force on August 16th 2016. The new chapter...
Brexit Clinical Trials Sector Implications
In this extract from our first Brexit whitepaper we look at the implications of Brexit for the clinical trials sector.
